Gofen & Glossberg LLC IL increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 21.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,754 shares of the medical instruments supplier’s stock after purchasing an additional 5,810 shares during the quarter. Gofen & Glossberg LLC IL’s holdings in Becton, Dickinson and were worth $6,418,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of BDX. Koch Industries Inc. lifted its holdings in Becton, Dickinson and by 45,268.7% in the second quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock worth $1,391,000 after purchasing an additional 1,395,182 shares during the period. Vanguard Group Inc. raised its position in Becton, Dickinson and by 8.5% in the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after acquiring an additional 1,353,780 shares in the last quarter. Winslow Capital Management LLC bought a new stake in Becton, Dickinson and in the second quarter worth about $225,164,000. Janus Henderson Group PLC raised its position in Becton, Dickinson and by 1,265.9% in the second quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock worth $236,245,000 after acquiring an additional 1,122,191 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in Becton, Dickinson and by 216.2% in the second quarter. Parametric Portfolio Associates LLC now owns 1,320,259 shares of the medical instruments supplier’s stock worth $257,596,000 after acquiring an additional 902,761 shares in the last quarter. 88.60% of the stock is owned by institutional investors and hedge funds.

Several brokerages have commented on BDX. Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 price target on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Royal Bank of Canada reiterated a “sector perform” rating and issued a $230.00 price target (up from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley boosted their price target on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Wells Fargo & Company reiterated a “positive” rating and issued a $235.00 price target (up from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Becton, Dickinson and currently has a consensus rating of “Buy” and a consensus price target of $217.08.

Becton, Dickinson and Company (NYSE:BDX) opened at $218.94 on Thursday. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. Becton, Dickinson and Company has a 12 month low of $161.50 and a 12 month high of $229.68. The firm has a market capitalization of $49,924.97, a PE ratio of 23.08, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter in the previous year, the business posted $2.12 EPS. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. equities research analysts forecast that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be paid a $0.75 dividend. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 7th. This represents a $3.00 annualized dividend and a dividend yield of 1.37%. Becton, Dickinson and’s payout ratio is presently 64.52%.

WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/gofen-glossberg-llc-il-has-6-42-million-stake-in-becton-dickinson-and-company-bdx/1763282.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with Analyst Ratings Network's FREE daily email newsletter.